LACTOLOGY FOUNDATION

Antituberculosis Drugs

💊 Mechanisms, classification, adverse effects and strategies to combat resistance

I. Specific Features of Mycobacterium tuberculosis

• Slow division: requires prolonged therapy (minimum 6 months).
• Acid fastness: lipid‑rich cell wall → poor drug penetration.
• Latency: ability to “sleep” inside macrophages → possible reactivation years later.
• Drug resistance: high risk with inadequate regimens → MDR‑TB (multidrug‑resistant), XDR‑TB (extensively drug‑resistant).

From a lactation perspective, these properties explain why long, multidrug regimens are needed and why breastfeeding mothers must adhere strictly to treatment to prevent resistance and relapse.droracle+1

II. First‑Line Antituberculosis Drugs

(Used in drug‑susceptible, uncomplicated tuberculosis)

1. Isoniazid (INH)

Mechanism
Inhibits synthesis of mycolic acids, a key component of the mycobacterial cell wall.

Adverse effects

• Hepatotoxicity (risk increased in alcohol use and older age).
• Peripheral neuropathy → preventable with vitamin B6 (pyridoxine).

Key feature
Bactericidal against rapidly dividing bacilli.

Lactation note
Isoniazid passes into breast milk in low concentrations; infant exposure is estimated at ≤10% of the therapeutic infant dose and is generally not associated with clinically significant adverse effects. Breastfeeding is not contraindicated during maternal INH therapy, but maternal pyridoxine 25–50 mg/day is recommended, and breastfed infants should be clinically monitored, especially for jaundice.pmc.ncbi.nlm.nih+4

2. Rifampicin (RIF)

Mechanism
Inhibits DNA‑dependent RNA polymerase → blocks transcription.

Adverse effects

• Reddish discoloration of tears and urine (benign).
• Hepatotoxicity (especially combined with INH).
• Potent CYP450 inducer → reduces the effect of many drugs (oral contraceptives, warfarin).

Key feature
Active against latent bacilli → critical for prophylaxis.

Lactation note
Rifampicin is excreted into breast milk in small amounts; available data and expert consensus indicate that these levels are unlikely to cause toxicity, and breastfeeding may generally continue during therapy. However, CYP induction may reduce the efficacy of progestin or combined hormonal contraception in lactating women, so non‑hormonal or alternative contraceptive methods should be discussed.cdc+3

3. Pyrazinamide (PZA)

Mechanism
Active only in acidic environments (inside macrophages) → disrupts mycobacterial cell membrane and energy production.

Adverse effects

• Hepatotoxicity.
• Hyperuricemia (gout‑like arthralgia).

Key feature
Bactericidal against slowly metabolizing or semi‑dormant bacilli.

Lactation note
Data on pyrazinamide in breastfeeding are more limited, but available reports suggest low levels in milk and no consistent signal of toxicity in nursing infants. Most guidelines allow breastfeeding while the mother receives standard first‑line regimens including PZA, with infant monitoring for liver function and clinical status on a case‑by‑case basis.ncbi.nlm.nih+4

4. Ethambutol (EMB)

Mechanism
Inhibits synthesis of arabinogalactan, an essential component of the cell wall.

Adverse effects

• Optic neuritis → impaired color discrimination and reduced visual acuity (mandatory ophthalmologic monitoring).

Key feature
Primarily bacteriostatic.

Lactation note
Ethambutol appears in breast milk at low concentrations and is considered compatible with breastfeeding in standard doses, with no significant toxicity reported in breastfed infants. Routine ophthalmologic monitoring is for the mother; in infants, visual behavior and development should be observed during prolonged maternal therapy.e-lactancia+2

III. Standard Regimen for Drug‑Susceptible TB

“2HRZE/4HR”

• First 2 months (intensive phase): INH + RIF + PZA + EMB.
• Following 4 months (continuation phase): INH + RIF.

Goal: rapid reduction of bacterial load and prevention of resistance.

Lactation note
Most first‑line agents (INH, RIF, EMB, often PZA) are considered compatible with breastfeeding; concentrations in milk are insufficient to treat the infant, so exposed infants still require full prophylactic or therapeutic doses when indicated. Breastfeeding is usually encouraged once the mother is non‑infectious and adherent to therapy, given the nutritional and immunological benefits of breast milk.pubmed.ncbi.nlm.nih+3

IV. Second‑Line Drugs

(Used in MDR‑TB, XDR‑TB or intolerance to first‑line agents)

💡 New agents such as bedaquiline, delamanid and pretomanid represent a major advance in XDR‑TB treatment.

Lactation note
Evidence for most second‑line drugs in breastfeeding is sparse; in general, benefits of maternal treatment must be weighed against potential infant risk. For highly toxic agents (e.g. aminoglycosides, certain fluoroquinolones or novel MDR‑TB drugs), some experts consider temporary interruption of breastfeeding or close infant monitoring (renal function, hearing, hematology, ECG) depending on the regimen and local policy.wellcomeopenresearch+2

V. Regimens for MDR/XDR‑TB

• Minimum of 5 active drugs for 18–24 months.

Typically include:

• A fluoroquinolone (e.g. levofloxacin).
• An injectable agent (amikacin or capreomycin).
• Bedaquiline and/or delamanid.
• Linezolid.
• Cycloserine and/or PAS (para‑aminosalicylic acid).

Lactation note
In MDR/XDR‑TB the priority is effective maternal cure; breastfeeding decisions must be individualized, ideally using a multidisciplinary team (TB specialist, neonatologist, lactation expert). If breastfeeding continues, infants need careful clinical follow‑up and, where indicated, chemoprophylaxis and ECG or laboratory monitoring.e-lactancia+1

VI. Adverse Effects: Monitoring Is Vital

For breastfeeding women, the same monitoring applies, with additional attention to infant clinical status (feeding, weight gain, jaundice, behavior) during maternal therapy.ncbi.nlm.nih+2

VII. Golden Rules for Successful Treatment

• Combination therapy: always at least 3 active drugs (monotherapy rapidly selects resistance).
• Duration: do not interrupt therapy; non‑adherence dramatically increases the risk of MDR/XDR‑TB.
• DOTS (Directly Observed Therapy): supervised dosing improves adherence and outcomes.
• Latent TB: prophylaxis with INH for 9 months or RIF for 4 months.

Lactation note
Preventive therapy for latent TB can be given to breastfeeding women; first‑line regimens are generally compatible with lactation, though some guidelines suggest timing INH after a feed and adding maternal pyridoxine. Breastfed infants who receive isoniazid prophylaxis should also receive pyridoxine supplementation.ncbi.nlm.nih+3

VIII. Challenges and Future Directions

• Resistance: MDR‑TB (resistant to INH + RIF), XDR‑TB (MDR pattern plus resistance to a fluoroquinolone and an injectable agent).

New developments include:

• Bedaquiline and delamanid, enabling shorter MDR‑TB regimens (6–9 months in selected cases).wellcomeopenresearch
• Candidate vaccines under development (e.g. M72/AS01E).

Lactation note
Future regimens aim to be shorter and better tolerated, which is especially important for women of reproductive age who may be pregnant or breastfeeding during treatment. Integrating lactation safety data into TB trials remains a priority to support evidence‑based guidance for breastfeeding mothers.cdc+2

Clinical Tip

“Treating TB is a marathon, not a sprint. The patient must understand that a missed dose is enemy number one.”

For breastfeeding mothers, this message is doubly important: consistent therapy protects both the mother’s health and the infant’s long‑term outcomes while usually allowing continuation of breastfeeding under appropriate monitoring.droracle+1